The introduction of CAR-T therapy has revolutionized the myeloma treatment landscape, offering a promising therapeutic approach for patients with relapsed/refractory (R/R) disease. There are currently two approved CAR-T cells in multiple myeloma: idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), with ongoing studies exploring the possibility of bringing these agents into earlier lines of treatment.
In this podcast, Maria-Victoria Mateos, MD, PhD, University of Salamanca, Salamanca, Spain, Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, University College London Hospitals, London, UK, and Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, discuss the significance of CAR-T therapy in myeloma, how to select patients for CAR-T therapy, the evolving role of autologous stem cell transplantation (autoSCT), and more.
The post The impact of CAR-T therapy on the myeloma treatment landscape, patient selection for CAR-T & the evolving role of autoSCT appeared first on VJHemOnc.
